In vitro and in vivo activities of anti-influenza virus compound T-705
- PMID: 11897578
- PMCID: PMC127093
- DOI: 10.1128/AAC.46.4.977-981.2002
In vitro and in vivo activities of anti-influenza virus compound T-705
Abstract
T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has been found to have potent and selective inhibitory activity against influenza virus. In an in vitro plaque reduction assay, T-705 showed potent inhibitory activity against influenza A, B, and C viruses, with 50% inhibitory concentrations (IC(50)s) of 0.013 to 0.48 microg/ml, while it showed no cytotoxicity at concentrations up to 1,000 microg/ml in Madin-Darby canine kidney cells. The selectivity index for influenza virus was more than 2,000. It was also active against a neuraminidase inhibitor-resistant virus and some amantadine-resistant viruses. T-705 showed weak activity against non-influenza virus RNA viruses, with the IC(50)s being higher for non-influenza virus RNA viruses than for influenza virus, and it had no activity against DNA viruses. Orally administered T-705 at 100 mg/kg of body weight/day (four times a day) for 5 days significantly reduced the mean pulmonary virus yields and the rate of mortality in mice infected with influenza virus A/PR/8/34 (3 x 10(2) PFU). These results suggest that T-705 may be a compound that is useful and highly selective against influenza virus infections and that has a mode of action different from those of commercially available drugs, such as amantadine, rimantadine, and neuraminidase inhibitors.
Figures



Similar articles
-
[Favipiravir, a new concept of antiviral drug against influenza viruses].Rev Esp Quimioter. 2017 Apr;30(2):79-83. Epub 2017 Feb 8. Rev Esp Quimioter. 2017. PMID: 28176519 Review. Spanish.
-
Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.Antiviral Res. 2016 Aug;132:170-7. doi: 10.1016/j.antiviral.2016.06.007. Epub 2016 Jun 16. Antiviral Res. 2016. PMID: 27321665
-
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.Antivir Chem Chemother. 2003 Sep;14(5):235-41. doi: 10.1177/095632020301400502. Antivir Chem Chemother. 2003. PMID: 14694986
-
In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.Antimicrob Agents Chemother. 2010 Jun;54(6):2517-24. doi: 10.1128/AAC.01739-09. Epub 2010 Mar 29. Antimicrob Agents Chemother. 2010. PMID: 20350949 Free PMC article.
-
Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res. 2013 Nov;100(2):446-54. doi: 10.1016/j.antiviral.2013.09.015. Epub 2013 Sep 29. Antiviral Res. 2013. PMID: 24084488 Free PMC article. Review.
Cited by
-
Establishment of a High-Throughput Assay to Monitor Influenza A Virus RNA Transcription and Replication.PLoS One. 2015 Jul 21;10(7):e0133558. doi: 10.1371/journal.pone.0133558. eCollection 2015. PLoS One. 2015. PMID: 26196128 Free PMC article.
-
New treatments for influenza.BMC Med. 2012 Sep 13;10:104. doi: 10.1186/1741-7015-10-104. BMC Med. 2012. PMID: 22973873 Free PMC article. Review.
-
Management of respiratory viral infections in hematopoietic cell transplant recipients.Am J Blood Res. 2012;2(4):203-18. Epub 2012 Nov 25. Am J Blood Res. 2012. PMID: 23226621 Free PMC article.
-
The impact of high-resolution structural data on stemming the COVID-19 pandemic.Curr Opin Virol. 2021 Aug;49:127-138. doi: 10.1016/j.coviro.2021.05.005. Epub 2021 Jun 3. Curr Opin Virol. 2021. PMID: 34130040 Free PMC article. Review.
-
The association between QT interval changes and the treatment protocols of COVID-19 patients.North Clin Istanb. 2022 Jul 7;9(3):199-206. doi: 10.14744/nci.2022.86836. eCollection 2022. North Clin Istanb. 2022. PMID: 36199861 Free PMC article.
References
-
- Crotty, S., D. Maag, J. J. Arnold, W. Zhong, J. Y. N. Lau, Z. Hong, R. Andino, and C. E. Cameron. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375-1379. - PubMed
-
- Dolin, R., C. R. Richard, M. H. Paul, M. Raina, N. L. Pamela, and W. J. Joan. 1982. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N. Engl. J. Med. 307:580-584. - PubMed
-
- Eggleston, M. 1987. Clinical review of ribavirin. Infect. Control 8:215-218. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials